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Introduction
Ankylosing spondylitis (AS) is an inflammatory disorder of unknown cause that features arthritis of the spine and sacroiliac joints, oligoarthritis of peripheral joints, and inflammation of tendons, ligaments, and joint capsule insertion sites. The onset of the disease usually begins in the second or third decade of life with a male to female prevalence of 3:1.
1 Patients generally experience a gradual onset of back stiffness and pain radiating to the buttocks with symptoms progressing in an ascending fashion. Peripheral arthritis of hips, shoulders and knees may be transient or permanent. Advanced disease can involve fusion of the entire spine. AS is correlated with HLA-B27 antigen positivity, and patients test negative for serum rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Disease activity in AS can be measured with non-specific inflammatory serum markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), or with a standardized questionnaire such as the bath ankylosing spondylitis disease activity index (BASDAI).
Vitamin D is a secosteroid hormone with a well-established role in calcium and phosphate homeostasis, and in the regulation of bone formation and resorption, however it is now known that vitamin D is much broader. Studies have shown vitamin D functions as an endogenous immunomodulator. Vitamin D alters gene expression that affects cellular functions, such as apoptosis, differentiation, and proliferation. 2 Alterations in vitamin D receptors have been linked to autoimmune conditions, with some studies suggesting an association between vitamin D deficiency and autoimmune disease. 3 As such, there has been increasing interest in studying vitamin D levels in patients with autoimmune conditions.
Osteoporosis is a well-known feature of AS, and studies have suggested that lower bone mineral density and higher bone turnover may be related to inflammation. 4 Thus it stands to reason that vitamin D levels may bear some relation to disease activity in AS. There have been a handful of clinical investigations over the last 20 years looking at what role vitamin D, or deficiency thereof, may play in AS. The aim of this review study is to summarize this research and to address two questions. First, do serum 25-hydroxyvitamin D 3 levels correspond to disease activity in patients with AS? Second, is there any difference between serum 25-hydroxyvitamin D 3 levels in patients with AS when compared to healthy control subjects?
Methods
A literature search was ran using the PubMed and Embase databases for English language peer-reviewed papers that examined either serum vitamin D levels in AS patients as compared to healthy controls, or the correlation between vitamin D levels in AS patients and disease activity. The keywords "vitamin D" and "ankylosing spondylitis" were used. All references cited by these papers were reviewed to locate additional studies not referenced in the aforementioned databases. Single case reports, review articles and studies that included patients with other autoimmune conditions other than AS in their analyses were excluded.
We identified 11 studies in total meeting these criteria, [4] [5] [6] [7] [8] [9] [10] [11] [12] among those, 8 were case-control studies, and 3 were caseonly cross-sectional studies.
Vitamin D levels and disease activity
To evaluate the relationship between vitamin D levels and measures of disease activity, both cross-sectional and casecontrol studies were reviewed. Of the 11 studies that were retrieved, 7 studies examined the correlation between vitamin D levels and indicators of disease activity in AS. This included 6 suitable case-control studies and 1 cross-sectional caseonly study. Collectively, this represented 573 patients, 82% of whom were male, with a mean age of 38.9 years.
The most common indicators of disease activity used were the bath ankylosing spondylitis index (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). All studies used the Spearman correlation coefficient to study the relationship between variables. For the purposes of this analysis, p<0.05 was taken as statistically significant. All studies compared disease activity with serum levels of 25-hy-droxyvitamin D 3 , except for the two studies by Lange that measured serum 1,25-dihydroxyvitamin D 3 levels. [4] [5] The results are summarized in Table 1 .
Four of 7 studies (encompassing 52% of the total patients) found a significant negative correlation between BASDAI and vitamin D levels, while the other 3 studies did not find a significant association. Significant negative correlations with vitamin D levels were noted for both ESR and CRP in 4 of 7 studies (encompassing 48% of total patients).
Vitamin D levels in ankylosing spondylitis
Eight case-control studies that compared vitamin D levels in a total of 555 AS patients and 557 healthy controls were identified. The mean age of these patients was 39.4 years, and 78.0% were male. Results are summarized in Table 2 . The study by Yazmalar et al. studied vitamin D levels over summer and winter in the same set of patients. 11 As the vitamin D levels did not vary significantly between seasons, they were averaged.
Five of 8 studies found that patients with AS had significantly lower vitamin D levels than controls, while 3 studies found no significant difference. The average 25-hydroxyvitamin D level over all studies was (22.8±14.1) ng/mL in AS patients and (26.6±12.5) ng/mL in healthy controls. When compared with a 2-sample t test, the vitamin D levels were significantly higher in healthy controls (3.8±0.8 ng/mL, p<0.01). Only 6 of 8 studies compared ESR and CRP between healthy subjects and those with AS, but the serum levels of both markers were found to be significantly higher in patients with AS in all 6 of these studies.
Discussion
The vitamin D receptor gene is expressed in many immune cells. 13 Vitamin D regulates both innate and adaptive immunity suppressing adaptive immunity (B and T lymphocyte functions) and potentiates the innate response (monocytes, macrophages and antigen presenting cells). 14 The first aim of this review was to examine existing studies in order to determine if vitamin D levels in patients with AS correspond to disease activity.
The activity of many rheumatological diseases including AS can be measured with CRP and ESR, which are non-specific but provide some objective indication of inflammation. Several newer biomarkers which hope to offer better specificity are under investigation including matrix metalloproteinases (MMP-3), type II collagen epitopes, and interleukin-6 (IL-6). 15 The bath ankylosing spondylitis disease activity index (BASDAI) was developed in 1994 and provides a standardized method of assessing disease activity as it relates to patients' symptoms and quality of life. Although some newer models have been developed, BASDAI remains the most widely-used tool to assess disease activity in patients with AS. 16 The studies in this analysis had conflicting data regarding the correlation of vitamin D levels with ESR, CRP and BASDAI scores. Also of note, most of the statistically significant correlations were weak (r 2 <0.6). The existing studies are inconclusive as to whether serum vitamin D levels bear any significant correlation to systemic inflammation or disease activity in patients with AS. This echoes what has been seen in similar studies looking at activity of other rheumatological diseases. 3 The results in the literature are mixed, with some of studies finding an association between vitamin D levels and disease activity in SLE and RA, and other studies unable to reproduce these results.
The next question which we sought to address was whether vitamin D levels were different in patients with AS. Vitamin D insufficiency has been described as a pandemic, with as many as one billion people worldwide insufficient or deficient in vitamin D. 17 There is no universal consensus on what constitutes an ideal serum level of 25-hydroxyvitamin D 3 . In a 2011 clinical practice guideline, the Endocrine Society stated an ideal serum level would be at least 30 ng/mL (75 nmol/L). 18 Serum levels between 21-29 ng/mL are defined as vitamin D insufficiency, and levels 20 ng/mL or below are considered vitamin D deficiency.
When data among the 8 studies we reviewed were pooled, it was found that patients with AS have significantly lower vitamin D levels as compared to healthy controls. The average vitamin D levels among AS patients in all 8 studies were insufficient or deficient. It is also interesting to note that mean vitamin D levels were also insufficient in the healthy controls in 5 of 8 studies.
Overall, the findings correspond with other cross-sectional studies which showed that deficient serum levels of vitamin 19 systemic lupus erythematosus and rheumatoid arthritis (RA). 20 As pointed out by Welsh et al. 21 in a review of vitamin D levels and RA, the cross-sectional studies included in this analysis are limited as they cannot rule out reverse causality. Thus, with the existing studies it is not possible to ascertain whether vitamin D deficiency is a cause, or a consequence, of AS.
Tumor necrosis factor alpha (TNF-α) is thought to play a role in chronic inflammation, and it is known to inhibit the binding of the vitamin D receptor to vitamin D responsive element (VDRE) of the osteocalcin gene. It may down-regulate the 24-hydroxylase activity in kidneys, possibly reducing vitamin D levels. 8 There has been some suggestion in the literature that vitamin D, as with other circulating vitamins, may be subject to an inverse acute phase response. 22 In other words, systemic inflammation may lower circulating levels of vitamin D.
On the other hand, vitamin D has been reported to inhibit expression of TNF-α, 23 and it follows that vitamin D deficiency may accelerate inflammation. Lange et al. noted a negative correlation between vitamin D levels and TNF-α in patients with AS. 4 Prospective studies suggest vitamin D deficiency is associated with an increased risk of RA development. 24 Well-designed prospective studies are required to determine whether vitamin D status has any relationship to the development of AS.
There are several possible explanations of the heterogeneity in the results. The studies used in this analysis had different sizes and statistical powers, and varied in their control of confounding factors. All these studies reported exclusion of patients with chronic and systemic diseases, but use of glucocorticoids, biological agents, bisphosphonates, and vitamin D supplementation itself was not controlled in all of them. The studies had differing percentages of male and female patients, and seasonality was not controlled in of those. Yazmalar et al. have found that although circulating levels of 25(OH) vitamin D do not vary significantly over the seasons, BASDAI scores are higher in winter months. 11 It is also known that circulating vitamin D levels are affected by body mass index, skin pigmentation, latitude, clothing and sunscreen use, 25 and it is not clear whether all of these studies controlled for these confounders.
Conclusion
In conclusion, patients with AS, as in other autoimmune diseases, appear to have lower vitamin D levels than healthy controls, however the cause is unclear. In studies to date, there has been no consistent link between vitamin D levels and disease activity in AS, neither evidence at this point that would justify the use of serum 25-hydroxyvitamin D 3 levels as a marker of disease activity. It remains to be seen whether vitamin D deficiency can predispose to the development of AS and if maintenance of optimal vitamin D levels can improve outcomes in AS.
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